Who are naratriptan HCl's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Migranal nasal spray at 4 hour, Migranal nasal spray at 1 hour, Sumatriptan Succinate Oral Tablet, sumatriptan succinate/naproxen sodium, NP101 - Sumatriptan iontophoretic transdermal patch, Placebo to rizatriptan tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/naratriptan-hcl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

naratriptan HCl — Competitive Intelligence Brief

naratriptan HCl (naratriptan HCl) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triptan (5-HT1B/1D receptor agonist). Area: Neurology.

marketed Triptan (5-HT1B/1D receptor agonist) 5-HT1B receptor, 5-HT1D receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

naratriptan HCl (naratriptan HCl) — Cady, Roger, M.D.. Naratriptan selectively binds to serotonin 5-HT1B/1D receptors on cranial blood vessels and nerve terminals to constrict blood vessels and inhibit neuropeptide release, thereby relieving migraine headaches.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
naratriptan HCl TARGET	naratriptan HCl	Cady, Roger, M.D.	marketed	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor
Migranal nasal spray at 4 hour	Migranal nasal spray at 4 hour	Thomas Jefferson University	marketed	Ergot alkaloid; 5-HT1B/1D receptor agonist	5-HT1B receptor, 5-HT1D receptor
Migranal nasal spray at 1 hour	Migranal nasal spray at 1 hour	Thomas Jefferson University	marketed	Ergot alkaloid; serotonin receptor agonist	5-HT1B receptor, 5-HT1D receptor
Sumatriptan Succinate Oral Tablet	Sumatriptan Succinate Oral Tablet	Damanhour Teaching Hospital	marketed	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor
sumatriptan succinate/naproxen sodium	sumatriptan succinate/naproxen sodium	GlaxoSmithKline	marketed	5-HT1B/1D receptor agonist combined with NSAID	5-HT1B receptor, 5-HT1D receptor, COX-1, COX-2
NP101 - Sumatriptan iontophoretic transdermal patch	NP101 - Sumatriptan iontophoretic transdermal patch	NuPathe Inc.	phase 3	5-HT1B/1D receptor agonist (triptan)	5-HT1B receptor, 5-HT1D receptor
Placebo to rizatriptan tablets	Placebo to rizatriptan tablets	Merck Sharp & Dohme LLC	phase 3	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triptan (5-HT1B/1D receptor agonist) class)

Organon and Co · 3 drugs in this class
Cady, Roger, M.D. · 1 drug in this class
Damanhour Teaching Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Teva Pharmaceuticals USA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). naratriptan HCl — Competitive Intelligence Brief. https://druglandscape.com/ci/naratriptan-hcl. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab